Severe Acquired Factor VIII Deficiency With Concomitant Lupus Anticoagulant: A Case Report

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by autoantibodies against factor VIII (F VIII). The coexistence of AHA with lupus anticoagulant (LAC) is incredibly uncommon and presents a significant diagnostic challenge, as both conditions prolong activated partial thromboplastin time (aPTT) and demonstrate incomplete correction on mixing studies. We report a case of a 79-year-old man with no prior bleeding history who presented with severe anemia and a retroperitoneal hematoma following a fall. Laboratory evaluation revealed markedly prolonged aPTT, severely reduced F VIII activity (<7%), and an exceptionally elevated inhibitor titer (1084 Bethesda units), consistent with AHA. Concurrently, anticoagulant testing was done with a positive LAC presence. Extensive workup failed to identify an underlying etiology. The patient was subsequently treated with rituximab and corticosteroids, resulting in a gradual decline in aPTT and inhibitor titers with clinical improvement. This case highlights the importance of comprehensive coagulation testing in patients with unexplained bleeding and prolonged aPTT, as the coexistence of prothrombotic and hemorrhagic conditions can obscure diagnosis and delay appropriate management.

Authors

Publication Details

Journal
Cureus
Published
2026-07-23
DOI
https://doi.org/10.7759/cureus.113229
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Severe Acquired Factor VIII Deficiency With Concomitant Lupus Anticoagulant: A Case Report

J K Suh, Ammar Khawar, Tae Hoon Kim
Cureus
Hemophilia Treatment and Research
article

Severe Acquired Factor VIII Deficiency With Concomitant Lupus Anticoagulant: A Case Report

J K Suh, Ammar Khawar, Tae Hoon Kim
article en

Abstract

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by autoantibodies against factor VIII (F VIII). The coexistence of AHA with lupus anticoagulant (LAC) is incredibly uncommon and presents a significant diagnostic challenge, as both conditions prolong activated partial thromboplastin time (aPTT) and demonstrate incomplete correction on mixing studies. We report a case of a 79-year-old man with no prior bleeding history who presented with severe anemia and a retroperitoneal hematoma following a fall. Laboratory evaluation revealed markedly prolonged aPTT, severely reduced F VIII activity (<7%), and an exceptionally elevated inhibitor titer (1084 Bethesda units), consistent with AHA. Concurrently, anticoagulant testing was done with a positive LAC presence. Extensive workup failed to identify an underlying etiology. The patient was subsequently treated with rituximab and corticosteroids, resulting in a gradual decline in aPTT and inhibitor titers with clinical improvement. This case highlights the importance of comprehensive coagulation testing in patients with unexplained bleeding and prolonged aPTT, as the coexistence of prothrombotic and hemorrhagic conditions can obscure diagnosis and delay appropriate management.

Cureus
Good health and well-being
Openalex Percentile: Top 10%
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.